Clinical trials: Semaglutide
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects…
- Trial name
- NCT05064735
- Testing
- semaglutide 2.4 mg
- Where
- 122 sites in United States, Canada and 9 more
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
FutureShape Family
The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor…
- Trial name
- NCT07872904
- Testing
- Family Care, Standard Care, Semaglutide (administered by PDS290 pen-injector)
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Stage 1 Diabetes Mellitus, Type 1
GLP-1 RA for Stage 1 Type 1 Diabetes
This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes.
- Trial name
- NCT07430332
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Lactation, Weight Loss
Effects of GLP-1 RAs on Human Lactation Outcomes
There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk.
- Trial name
- NCT07720414
- Testing
- Injected GLP-1 Receptor Agonists and Dual Agonists
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying
GLP_1 RA Ultrasound Study
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes
- Trial name
- NCT06581120
- Testing
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati